Amarin Corp Plc (AMRN)

[Biobillionair]

Longs please read #2

As a stated in post #18686 (read the document, it's short)

The Ad Com tone wasn't approved by ORP in my opinion, thus it had to contain both #1 & #2 caution statement.

Beyond this:
The FDA openly discussed canceling SPA, this is a violation of "new" policy

The FDA disclaimed, Vascepa was not a NME when discussing why they didn't provide safety data.

I called multiple FDA channels yesterday requesting minutes be posted...hasn't happened yet but we do have audio.

Can anyone make a written document of:
1) the SPA discussion
2) the request to change question
3) leading up to and following the "NME" slip?

The Ad Com as a whole was materially damaging to Amarin, and violated numerous FDA policy's.


Investors with either option losses, or margin calls should initiate action immediatly. Longs can only hope the FDA hasn't permanently damaged company....

Investors should start to look at legal recourse towards FDA ASAP!